BRIEF-Mesoblast says US FDA grants fast track designation for GVHD
March 06, 2017 at 17:54 PM EST
* FDA grants fast track designation for Mesoblast's cell therapy in children with Acute Graft Versus Host Disease Source text for Eikon: Further company coverage:
